alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Home › Research › Topics › semaglutide

semaglutide

9 studies tagged semaglutide, dated 2024-06-13 to 2026-02-25. Bibliography: BibTeX (.bib) · RIS (.ris)

Newest in this topic

  1. Tirzepatide versus semaglutide for the prevention of mild cognitive impairment, dementia, and Alzheimer's disease in type 2 diabetes: A real-world, retrospective cohort study 2026-02-25
  2. Baseline characteristics from evoke and evoke+: Two phase 3 randomized placebo-controlled trials of semaglutide in participants with early-stage symptomatic Alzheimer's disease 2026-01-10
  3. Targeting neuroinflammation in neurodegenerative disorders: the emerging potential of semaglutide 2026-01-08

Studies

9 studies carry this tag.

Date range

2024 to 2026

Top journals

  • Alzheimer's & dementia (New York, N. Y.) 2
  • Alzheimer's & dementia : the journal of the Alzheimer's Association 1
  • Biomedicines 1
  • Current issues in molecular biology 1
  • Future science OA 1

8 journals in all.

Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.

  1. Tirzepatide versus semaglutide for the prevention of mild cognitive impairment, dementia, and Alzheimer's disease in type 2 diabetes: A real-world, retrospective cohort study

    ✓ Peer-reviewed alzhub usefulness score 79 out of 100. Journal of diabetes and its complications 2026-02-25 Drug development

    A total of 290,606 patients initiated semaglutide and 44,471 initiated tirzepatide.

  2. Baseline characteristics from evoke and evoke+: Two phase 3 randomized placebo-controlled trials of semaglutide in participants with early-stage symptomatic Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 74 out of 100. Alzheimer's & dementia (New York, N. Y.) 2026-01-10 Drug development

    Inclusion criteria are the same for both trials, except that by design, evoke+ also includes participants with significant small vessel pathology.

  3. Targeting neuroinflammation in neurodegenerative disorders: the emerging potential of semaglutide

    ✓ Peer-reviewed alzhub usefulness score 43 out of 100. Inflammation research : official journal of the European Histamine Research Society ... [et al.] 2026-01-08 Drug development

    Within this framework, we evaluate the therapeutic potential of semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA) with emerging neuroprotective properties.

  4. The multifaceted effects of semaglutide: exploring its broad therapeutic applications

    ✓ Peer-reviewed alzhub usefulness score 45 out of 100. Future science OA 2025-09-03 Drug development

    Semaglutide, a GLP-1 receptor agonist, is FDA-approved for managing type 2 diabetes (T2D) and reducing cardiovascular risk.

  5. Safety considerations of semaglutide in the potential treatment of Alzheimer's disease: A pooled analysis of semaglutide in adults aged ≥ 65 years

    ✓ Peer-reviewed alzhub usefulness score 62 out of 100. Alzheimer's & dementia (New York, N. Y.) 2025-04-01 Drug development

    Age ≥ 65 years did not appear to affect the safety considerations of semaglutide.

  6. Exploring the Impact of Semaglutide on Cognitive Function and Anxiety-Related Behaviors in a Murine Model of Alzheimer's Disease

    ✓ Peer-reviewed alzhub usefulness score 45 out of 100. Biomedicines 2024-11-25 Drug development

    The findings of this pilot study suggest that SEM may play a dual role in managing AD by improving glycemic control and potentially enhancing cognitive function.

  7. Semaglutide promotes the transition of microglia from M1 to M2 type to reduce brain inflammation in APP/PS1/tau mice

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. Neuroscience 2024-11-14 Drug development

    A growing number of studies show that the diabetes drug Semaglutide is neuroprotective in Alzheimer's disease (AD) animal models, but its mode of action is not fully understood.

  8. Associations of semaglutide with first-time diagnosis of Alzheimer's disease in patients with type 2 diabetes: Target trial emulation using nationwide real-world data in the US

    ✓ Peer-reviewed alzhub usefulness score 48 out of 100. Alzheimer's & dementia : the journal of the Alzheimer's Association 2024-10-24 Drug development

    These findings support further studies to assess semaglutide's potential in preventing AD.

  9. Unlocking the Potential: Semaglutide's Impact on Alzheimer's and Parkinson's Disease in Animal Models

    ✓ Peer-reviewed alzhub usefulness score 45 out of 100. Current issues in molecular biology 2024-06-13 Drug development

    Semaglutide (SEM), a glucagon-like peptide-1 receptor agonist, has garnered increasing interest for its potential therapeutic effects in neurodegenerative disorders such as Alzheimer's disease (AD) and Parkinson's disease (PD).

All topic tags with their study counts